<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595425</url>
  </required_header>
  <id_info>
    <org_study_id>D961TC00001</org_study_id>
    <nct_id>NCT01595425</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Bioequivalence Study Comparing a Pellets Based Sachet Formulation of D961H 20 mg and a Commercial HPMC Capsule of D961H 20 mg After Repeated Oral Administration in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study is to investigate whether D961H sachet 20 mg is bioequivalent to D961H HPMC
      capsule 20 mg following repeated oral doses, and to evaluate the safety and tolerability of
      these two formulations in healthy male Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Bioequivalence Study
      Comparing a Pellets Based Sachet Formulation of D961H 20 mg and a Commercial HPMC Capsule of
      D961H 20 mg After Repeated Oral Administration in Japanese Healthy Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ and Cmax,ss of D961H</measure>
    <time_frame>Day 5</time_frame>
    <description>AUC(0-t)-Area under plasma concentration time curve from zero to time of the last measurable concentration
Cmax,ss - maximum concentration at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetic of D961H in terms of AUC0-t,ss, MRT, tmax,ss, and t1/2.</measure>
    <time_frame>Day 5</time_frame>
    <description>AUC0-t,ss-Area under plasma concentration time curve from zero to time of the last measurable concentration at steady state
MRT- Mean residence time
tmax,ss -time of maximum concentration at steady state
t½ -Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of a D961H in terms of clinical laboratory tests, blood pressure, pulse rate and body temperature.</measure>
    <time_frame>Up to 5 to 7 days after the last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events.</measure>
    <time_frame>Up to 5 to 7 days after the last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>D961H Sachet 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D961HHPMC Capsule 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H Sachet 20 mg</intervention_name>
    <description>Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.</description>
    <arm_group_label>D961H Sachet 20 mg</arm_group_label>
    <other_name>esomeprazole sachet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H HPMC capsule 20 mg</intervention_name>
    <description>Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.</description>
    <arm_group_label>D961HHPMC Capsule 20 mg</arm_group_label>
    <other_name>esomeprazole</other_name>
    <other_name>capsule 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures

          2. Japanese healthy male subjects aged 20 to 45 years of age

          3. Body Mass Index 19-27 kg/m2 and body weight 50-85 kg

          4. Clinically normal findings

          5. Classified as homo-EM(extensive metabolizers) according to the genotype of CYP2C19

        Exclusion Criteria:

          1. Significant clinical illness

          2. Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease

          3. Clinical significant condition which could modify the absorption of the
             investigational product

          4. Past or present severe allergic disease, hypersensitivity to food or drugs, or
             allergic symptoms requiring medical intervention
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masataka Date</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masanari Shiramoto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hakata Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Unit</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>safety,</keyword>
  <keyword>esomeprazole,</keyword>
  <keyword>Japanese,</keyword>
  <keyword>healthy subject,</keyword>
  <keyword>homo-EM</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

